MIMO Biosciences

What MIMO Biosciences does

MIMO Biosciences is a specialized contract research organization (CRO) focused on preclinical hematology and immuno-oncology, headquartered at the CIMA Universidad de Navarra campus in Pamplona, Spain. The company was founded in late 2023 as a spin-off after 12 years of academic research at CIMA, with its formation encouraged by pharmaceutical partner Bristol Myers Squibb. It operates with a small multidisciplinary team (~7 people) led by CEO Ricardo Pérez and CSO/Founder Jose A. Martínez-Climent.

The company's core offering is a proprietary portfolio of in-house preclinical mouse models — syngeneic, genetically engineered mouse models (GEMMs), GEMMs with human gene targets, patient-derived xenografts (PDX), and humanized xenograft models — designed to recapitulate the biology of hematological malignancies and to evaluate immunotherapies including CAR-T, bispecific antibodies, and CELMoDs. These models are bundled with integrated service lines covering drug development and safety, in vivo imaging and disease tracking (microPET, histopathology, multiparametric flow cytometry), molecular profiling (NGS, transcriptomics), and an AI-powered multi-omic data integration and analytics platform. Research has been published in Nature Medicine, Cancer Discovery, PNAS, Cancer Cell, and Blood.

MIMO generates revenue through negotiated, project-based preclinical research contracts with pharmaceutical and biotechnology clients. Pricing is not publicly disclosed; engagements are customized per drug target and study scope. The customer base is enterprise-only and includes Bristol Myers Squibb, Regeneron, AstraZeneca, Janssen, Roche/Genentech, and biotechs such as Palleon, Priothera, K36, Boston Gene, Biocytogen, and Gen-Way, with 15 research agreements signed over the past three years. The company pursues direct enterprise sales, supported by scientific content marketing, conference participation (e.g., EHA Congress), and the credibility of its publication track. A new laboratory and office facility on the CIMA campus was completed in January 2025, and the company closed a 2025 funding round with Sanitas, Gutinver, and Green Eyes to expand its proprietary model portfolio.

Name

MIMO Biosciences

Legal name

MIMO BIOSCIENCES S.L.

Website

https://mimobiosciences.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

MIMO Biosciences is a Pamplona, Spain-based preclinical CRO specializing in hematology and immuno-oncology, providing proprietary mouse models (syngeneic, GEMMs, PDX, humanized xenografts) and integrated research services to pharmaceutical and biotechnology clients developing blood cancer therapies.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Preclinical CRO services
• Hematology mouse models
• Immuno-oncology research
• Patient-derived xenografts
• Preclinical drug development

Headquarters

HQ city

Pamplona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Preclinical CRO Services: MIMO Biosciences generates revenue by providing specialized preclinical research services to pharmaceutical and biotechnology companies. Services include drug development support, toxicology and pharmacology studies, efficacy trials, biomarker validation, and large-scale efficacy testing using their proprietary mouse models.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

MIMO Biosciences is a specialized preclinical Contract Research Organization (CRO) providing customized mouse models and integrated research services for hematology and immuno-oncology drug development. The company delivers in-house developed syngeneic, genetically engineered (GEMM), humanized xenograft, and patient-derived xenograft (PDX) models, supported by drug safety testing, in vivo imaging, molecular profiling, and AI-powered data analytics. Services are sold as research agreements and preclinical projects to pharmaceutical and biotechnology companies.

Product overview

MIMO Biosciences is a specialized CRO (Contract Research Organization) in Hematology and Immuno-Oncology offering a comprehensive portfolio of preclinical mouse models and research services. The core product portfolio consists of five distinct model types: Syngeneic Models (immunocompetent mouse models for immuno-oncology), GEMMs (Genetically Engineered Mouse Models for multiple myeloma and lymphoma), GEMMs with Human Gene Targets (humanized models for antibody and CAR-T evaluation), PDX (Patient-Derived Xenografts for personalized medicine), and Humanized Xenograft Models (for immunotherapy development). These models are complemented by four integrated service offerings: Drug Development & Safety Services, In Vivo Imaging & Disease Tracking, Molecular Profiling Services (NGS-based), and an AI-powered Data Integration & Analysis Platform. All models are developed and validated in-house, with research consistently featured in top journals including Nature Medicine, Cancer Discovery, and Blood.

Differentiator

Problem solved

Functional benefit

Products and services

• Syngeneic Models Immunocompetent mouse models using murine tumor cell lines implanted into genetically similar host mice, enabling study of tumor-immune system interactions for immuno-oncology research. Sold to pharmaceutical and biotechnology clients as part of MIMO's preclinical CRO offerings.
• Genetically Engineered Mouse Models (GEMMs) Preclinical mouse models that faithfully reproduce key genetic alterations driving cancer initiation and progression, including MYC-driven models (MIcy1 and MI), the BI model of SMM progression, MMSET-BIC high-risk myeloma, TP53-BIC deleted aggressive myeloma, MYD88/Cd79b ABC-DLBCL, and CHIP-MDS-AML models. Sold to pharma and biotech clients for hematology and immuno-oncology research.
• GEMMs with Human Gene Targets Tumor transplants from GEMMs engrafted into humanized mice expressing specific human proteins as drug targets, including BCMA+CD3ε+CRBN, GPRC5D, CD38, CD19&CD20+CD3ε/CRBN, and CRBN+FcγR humanizations for myeloma and lymphoma research. Sold to pharma and biotech clients for evaluation of monoclonal antibodies, CAR-T cell therapies, bispecific antibodies, and CELMoDs.
• Patient-Derived Xenografts (PDX) Preclinical models involving direct implantation of fresh human tumor tissue into immunodeficient mice, capturing human tumor heterogeneity and complexity for precision medicine applications, including AML PDX models. Sold to pharma and biotech clients seeking personalized-medicine-grade preclinical models.
• Humanized Xenograft Models Advanced models reconstituted with human immune system components (CD34+ hematopoietic stem cells or peripheral immune cells) enabling evaluation of immunotherapies including CAR-T, bispecific antibodies, and CELMoDs in an in vivo human immune context. Sold to pharma and biotech clients developing immuno-oncology therapies.
• Drug Development & Safety Services Supports drug development from medicinal chemistry to toxicology and pharmacology studies, including molecular design and in vivo safety and biodynamic assessment using MIMO's proprietary models. Sold to pharma and biotech clients seeking end-to-end preclinical support.
• In Vivo Imaging & Disease Tracking Provides Micropet imaging, histopathology, and multiparametric flow cytometry for real-time disease progression tracking and detailed tissue and cell characterization across preclinical mouse models. Sold to pharma and biotech clients as part of MIMO's integrated CRO offerings.
• Molecular Profiling Services Cutting-edge genomic analysis utilizing Next Generation Sequencing (NGS) and genetic/transcriptomic analyses to identify biomarkers and mechanisms of action in murine models and human samples. Sold to pharma and biotech clients for biomarker discovery and mechanistic studies.
• Data Integration & Analysis Platform AI-powered platform integrating multi-omic and phenotypic data using advanced biostatistics and bioinformatics to transform complex preclinical data into actionable insights for therapy development. Sold to pharma and biotech clients as a value-add to MIMO's preclinical CRO engagements.

Quantifiable outcome

• 15 research agreements with major pharmaceutical companies in the last 3 years
• +1 more outcomes

Named customers11 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature6 records

Partnerships

15 partnerships are on record, tiered core and major.

• Dana-Farber Cancer InstitutecoreStrategic or Co-development PartnerScientific partnership as part of MIMO's worldwide scientific network for hematology and immuno-oncology research collaboration
• Harvard UniversitycoreStrategic or Co-development PartnerScientific partnership as part of MIMO's worldwide scientific network
• Broad InstitutecoreStrategic or Co-development PartnerScientific partnership as part of MIMO's worldwide scientific network
• Yale UniversitycoreStrategic or Co-development PartnerScientific partnership as part of MIMO's worldwide scientific network
• Oxford UniversitycoreStrategic or Co-development PartnerScientific partnership as part of MIMO's worldwide scientific network
• University of CambridgecoreStrategic or Co-development PartnerScientific partnership as part of MIMO's worldwide scientific network
• Mayo CliniccoreStrategic or Co-development PartnerScientific partnership as part of MIMO's worldwide scientific network
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerScientific partnership as part of MIMO's worldwide scientific network
• CNIO (Spanish National Cancer Research Centre)coreStrategic or Co-development PartnerScientific partnership as part of MIMO's worldwide scientific network
• Universidad de NavarracoreStrategic or Co-development PartnerParent institution and founding research center. MIMO emerged from 12 years of pioneering research at CIMA Universidad de Navarra and operates from its campus in Pamplona
• Bristol Myers SquibbcoreStrategic or Co-development PartnerMajor pharmaceutical partner and key supporter who pushed for the founding of MIMO Biosciences in late 2023; ongoing research collaboration
• RegeneronmajorStrategic or Co-development PartnerPharmaceutical research collaboration partner for preclinical drug development
• AstraZenecamajorStrategic or Co-development PartnerPharmaceutical research collaboration partner for preclinical drug development
• Janssen (Johnson & Johnson)majorStrategic or Co-development PartnerPharmaceutical research collaboration partner for preclinical drug development
• Roche/GenentechmajorStrategic or Co-development PartnerPharmaceutical research collaboration partner for preclinical drug development

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Emerging players

• EPL Bio Analytical Services: Specialized preclinical and bioanalytical CRO supporting small-molecule and biologics programs. Adjacent comparable to MIMO as a niche preclinical service provider, though with a different therapeutic emphasis.
• Xentech: Smaller French preclinical CRO specializing in oncology pharmacology and efficacy studies in mouse models. Comparable to MIMO in size and therapeutic focus, with overlap in syngeneic and xenograft efficacy work for biotech clients.
• Reaction Biology: Preclinical CRO offering in vitro and in vivo oncology, immuno-oncology, and cell biology services. Comparable to MIMO as a smaller specialty preclinical CRO serving pharma/biotech translational research needs.

Broad incumbents

• WuXi AppTec: Major Asia-based CRO/CDMO with preclinical biology and oncology model services as part of a much wider discovery-through-manufacturing platform. Overlaps with MIMO in preclinical CRO work but at vastly greater scale and broader service mix.
• Labcorp Drug Development: Diversified CRO with preclinical oncology and immuno-oncology capabilities as part of a much larger clinical and central lab franchise. Overlaps with MIMO in preclinical service offerings for pharma clients but at materially greater scale and breadth.
• Charles River Laboratories: Global CRO with a large preclinical and discovery services portfolio including oncology model offerings. Comparable to MIMO as a provider of preclinical research services to pharma/biotech, but vastly broader in scale, therapeutic scope, and geographic reach.

Direct peers

• Crown Bioscience: Preclinical CRO specializing in oncology with extensive syngeneic, PDX, and humanized mouse models. Closely comparable to MIMO in business model and core offering, with a similar focus on translational oncology drug development for pharma/biotech.
• The Jackson Laboratory: Non-profit biomedical research institute providing genetically engineered mouse models, PDX, and preclinical services to pharma/biotech. Comparable to MIMO as a source of specialized oncology and immuno-oncology mouse models for translational research.
• Champions Oncology: Preclinical oncology CRO built around PDX and patient-derived models for pharma translational research. Directly comparable to MIMO's PDX and humanized xenograft offering, serving similar customers with similar fee-for-service preclinical engagements.
• Oncodesign: European preclinical CRO with a strong oncology focus, offering translational and drug discovery services to pharma. Closely comparable to MIMO as a specialized preclinical partner serving similar heme/IO and oncology drug development workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mimo-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MIMO Biosciences